<DOC>
	<DOCNO>NCT01345019</DOCNO>
	<brief_summary>The purpose study determine denosumab non-inferior zoledronic acid treatment bone disease multiple myeloma .</brief_summary>
	<brief_title>Denosumab Compared Zoledronic Acid Treatment Bone Disease Subjects With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Bone Density Conservation Agents</mesh_term>
	<criteria>Documented evidence multiple myeloma ( per local assessment ; see section 7.2 ) : Monoclonal plasma cell bone marrow great equal 10 % and/or presence biopsyproven plasmacytoma , Monoclonal protein present serum and/or urine Radiographic ( Xray , computer tomography [ CT ] ) evidence least 1 lytic bone lesion ( least 1 focal lesion per magnetic resonance image [ MRI ] ) Plan receive receive primary frontline antimyeloma therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Age ≥ 18 year Adequate organ function , define follow criterion ( per central local laboratory value ; see section 7.2 ) : Serum aspartate aminotransferase ( AST ) ≤ 2.0 x upper limit normal ( ULN ) / Serum alanine aminotransferase ≤ ( ALT ) 2.0 x ULN/ Serum total bilirubin ≤ 2.0 x ULN/ Creatinine clearance ≥ 30 mL/min/ Serum calcium albuminadjusted serum calcium 2.0 mmol/L ( 8.0 mg/dL ) 2.9 mmol/L ( 11.5 mg/dL ) Written informed consent studyspecific procedure perform Nonsecretory multiple myeloma base upon standard Mcomponent criterion ( ie , measurable serum/urine Mcomponent ) unless baseline serum free light chain level elevate POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) Plasma cell leukemia More 30 day previous treatment ( screen ) antimyeloma therapy ( include radiotherapy single short course steroid [ ie , less equal equivalent dexamethasone 60 mg/day 4 day ] ) . Planned radiation therapy surgery bone ( include procedure perform randomization ) Prior administration denosumab Use oral bisphosphonates cumulative exposure 1 year More 1 previous dose IV bisphosphonate administration Prior history current evidence osteonecrosis/osteomyelitis jaw Active dental jaw condition require oral surgery , include tooth extraction Nonhealed dental/oral surgery , include tooth extraction Planned invasive dental procedure Evidence follow condition per subject selfreport medical chart review : Any prior invasive malignancy within 5 year randomization/ Any noninvasive malignancy treat curative intent knownactive disease within 5 year randomization/ Major surgery significant traumatic injury occur within 4 week randomization/ Active infection Hepatitis B virus Hepatitis C virus/ Known infection human immunodeficiency virus ( HIV ) / Active infection require IV antiinfective therapy Subject pregnant breast feeding , plan become pregnant within 5 month end treatment Female subject child bear potential willing use highly effective contraception treatment 5 month end treatment ( see section 6.3 ) Known sensitivity product administer study ( eg , mammalian derive product , calcium vitamin D ) Subject receive less 30 day since end experimental device drug ( market authorization indication ) Subject available followup assessment Any major medical psychiatric disorder opinion investigator , might prevent subject complete study interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>zoledronic acid</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>SRE</keyword>
	<keyword>skeletal-related event</keyword>
	<keyword>blood cancer</keyword>
	<keyword>lytic bone lesion</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>myeloma</keyword>
	<keyword>fracture</keyword>
	<keyword>spinal cord compression</keyword>
	<keyword>radiation bone</keyword>
	<keyword>surgery bone</keyword>
	<keyword>bisphosphonates</keyword>
	<keyword>Neoplasms , Plasma Cell</keyword>
	<keyword>Paraproteinemias</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasm Metastasis</keyword>
	<keyword>Bone Neoplasms</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Blood Protein Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>denosumab</keyword>
	<keyword>Neoplastic Processes</keyword>
	<keyword>Bone Diseases</keyword>
	<keyword>Diphosphonates</keyword>
	<keyword>Bone Density Conservation Agents</keyword>
</DOC>